We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Editing Reduces Symptoms of Parasite Infection in Models

By LabMedica International staff writers
Posted on 29 Jan 2019
Tropical disease researchers used the CRISPR/Cas9 genome-editing tool to interfere with the ability of certain parasitic worms to invade and reproduce in rodent model systems.

CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. More...
CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system from Streptococcus pyogenes is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.

Investigators at George Washington University (Washington, DC, USA) employed CRISPR/Cas9 to modify the genomes of the parasites Schistosoma mansoni and Opisthorchis viverrini. S. mansoni causes schistosomiasis, in which freshwater worms enter the body by burrowing through the skin. The parasites then move through the bloodstream to lodge primarily in the liver where they lay eggs and reproduce. O. viverrini is a river fluke infection transmitted through traditional Southeast Asian cuisines. Infection by this parasite has been identified as a major risk factor for the development of usually fatal bile duct cancer (cholangiocarcinoma).

Each of these parasites produces and secretes characteristic proteins during the reproductive process that cause damage to surrounding host tissues. In the case of S. manosi, one such protein is the enzyme omega-1 ribonuclease, while O. viverrini parasites produce the growth factor, liver fluke granulin (Ov-grn-1).

In two papers published in the January 15, 2019, online edition of the journal eLife the investigators described how using CRISPR/Cas9 to eliminate the gene for omega-1 ribonuclease in S. mansoni eggs and the gene for Ov-grn-1 in O. viverrini affected infection by these organisms in rodent models.

Gene-edited Schistosoma eggs failed to polarize Th2 cytokine responses in macrophage/T-cell co-cultures, while the volume of pulmonary granulomas surrounding omega1-mutated eggs following tail-vein injection into mice was vastly reduced. In O. viverrini gene editing resulted in rapid depletion of Ov-grn-1 transcripts and the encoded Ov-grn-1 protein. Gene-edited parasites colonized the biliary tract of hamsters and developed into adult flukes, but the infection resulted in reduced pathology as evidenced by attenuated biliary hyperplasia and fibrosis.

"The genes we "knocked out" using CRISPR/Cas9 resulted in markedly diminished symptoms of infection in our animal models," said one of the senior authors, Dr. Paul Brindley, professor of microbiology, immunology, and tropical medicine at George Washington University. "Our research also showed that this revolutionary new biomedical procedure -- CRISPR/Cas9 -- can be adapted to study helminth parasites, which are a major public health problem in tropical climates."

"These neglected tropical diseases affect more than a quarter of a billion people primarily living in Southeast Asia, sub-Saharan Africa, and Latin America," said Dr. Brindley. "CRISPR/Cas9 is a tool that may be used to limit the impact of these infections. As we work to better understand how these parasites invade and damage our bodies through this new technology, we will find new ideas for treatment and disease control."

Related Links:
George Washington University


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Collection and Transport System
PurSafe Plus®
Gel Cards
DG Gel Cards
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.